NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
21.76
-0.65 (-2.90%)
At close: Mar 28, 2025, 4:00 PM
20.86
-0.90 (-4.13%)
Pre-market: Mar 31, 2025, 7:40 AM EDT
NAMS Revenue
In the year 2024, NewAmsterdam Pharma Company had annual revenue of $45.56M with 223.37% growth. NewAmsterdam Pharma Company had revenue of $12.77M in the quarter ending December 31, 2024, with 1,490.54% growth.
Revenue (ttm)
$45.56M
Revenue Growth
+223.37%
P/S Ratio
45.06
Revenue / Employee
$670,044
Employees
68
Market Cap
2.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.56M | 31.47M | 223.37% |
| Dec 31, 2023 | 14.09M | -88.60M | -86.28% |
| Dec 31, 2022 | 102.69M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
NAMS News
- 4 weeks ago - NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib - Seeking Alpha
- 4 weeks ago - NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution - Seeking Alpha
- 4 weeks ago - NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - GlobeNewsWire
- 7 weeks ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 3 months ago - NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 3 months ago - NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts - Seeking Alpha